Arbutus Biopharma Corporation (ABUS)

Arbutus Biopharma Corporation (ABUS) is a healthcare company (biotechnology) based in the United States. The share price is $4.05, up 0.25% on the day, which values the company at $620.84M. Price as of 18 Nov 2026, 11:57 UTC, from Yahoo Finance.

Key facts

Share price
$4.05+0.25% today
Market value
$620.84M
P/E ratio
3.6×last 12 months
Funk Score
27/100
Against its own history
Well above its usual priceusual price $2.64
200-week average
$3.4318% above
Sector
Healthcare

Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

Arbutus Biopharma Corporation in more detail

ABUS trades at 3.6× its last twelve months' earnings, -24.5× next year's expected earnings, 3.4× sales. Measured against its own history, the price is 54% above what its usual multiples would imply ($2.64) — well above its usual price. It sits 18% above its 200-week average of $3.43.

Over the last five fiscal years Arbutus Biopharma Corporation has compounded revenue 15.3% a year. Its Funk Score is 27 out of 100 (financial strength 3.8, profitability 2.5, growth 4.7, value 0.0, each out of 10).

In its favour: More cash than debt. Worth checking: Altman Z in the distress zone; Share count keeps rising.

Arbutus Biopharma Corporation (ABUS): questions and answers

What is ABUS's P/E ratio?

Arbutus Biopharma Corporation trades at 3.6× its last twelve months' earnings and -24.5× next year's expected earnings.

What is Arbutus Biopharma Corporation's market cap?

Arbutus Biopharma Corporation is valued at $620.84M at a share price of $4.05.

Is ABUS overvalued or undervalued?

Against its own history, ABUS is well above its usual price: the price is 54% above the $2.64 implied by the median multiples it has traded at (price / sales, price / book). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.

Is ABUS above its 200-week moving average?

Yes. ABUS is 18.0% above its 200-week average of $3.43. Long-term investors watch that line because strong companies rarely trade below it for long.

How fast is Arbutus Biopharma Corporation growing?

Over the last five fiscal years Arbutus Biopharma Corporation's revenue grew 15.3% a year; over ten years revenue grew -4.9% a year.

Does ABUS pay a dividend?

Arbutus Biopharma Corporation does not currently pay a regular dividend.

Cite this page

Funkfolio, “Arbutus Biopharma Corporation (ABUS) stock: price, valuation and fundamentals”, data as of 18 November 2026. https://funkfolio.com/stock/ABUS

Underlying data: Yahoo Finance; company filings with the SEC.